Shots:

• The first patient has been dosed in P-III PACIFIC-9 study evaluating durvalumab (PD-L1) + monalizumab (NKG2A) or oleclumab (anti-CD73) in patients with unresectable, stage III NSCLC who have not progressed following definitive Pt.-based concurrent CRT. The study is looking to recruit patients across 200+ centres
• The focus of the study is to determine if the addition of monalizumab or oleclumab to SOC durvalumab improves outcomes for patients in this setting
• The first dosing has triggered a $50M milestone payment from AstraZeneca to Innate. Innate’s monalizumab is an immune checkpoint inhibitor targeting NKG2A receptors expressed on tumor-infiltrating cytotoxic CD8+ T cells and NK cells

Ref: Innate | Image: Innate